. Author manuscript; available in PMC: 2018 Jul 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2017 May 18;80(1):29–36. doi: 10.1007/s00280-017-3315-8

Table 3a. Summary of vismodegib PK parameters in plasma in patients with normal or impaired hepatic function after oral administration of vismodegib (150 mg QD).

Parameter		Normal^* n = 9	Mild^* n = 8	Moderate^* n = 6	Severe^* n = 3
AUC_{0–24 h} (μM h)	Median	409	605	562	368
AUC_{0–24 h} (μM h)	GMR (90% CI)	Comparator	1.24 (0.9–1.7)	1.31 (0.9–1.9)	0.86 (0.5– 1.4)
C_max, μM	Median	18.1	27.4	26.9	17.1
	GMR (90% CI)	Comparator	1.3 (0.95–1.8)	1.3 (0.9–1.8)	0.87 (0.5– 1.4)
C_ss, μM	Median	17	24.3	24.5	15.7
	GMR (90% CI)	Comparator	1.24 (0.9–1.7)	1.27 (0.9–1.8)	0.88 (0.6– 1.4)

AAG alpha-1-acid glycoprotein, AUC area under the curve, CI confidence interval, C_max peak serum concentration, Css average steady state concentration, GMR geometric mean ratio.

Normal (bilirubin [bili] < upper limit of normal [ULN]) ], mild (ULN < bili ≤ 1.5× ULN), moderate (1.5× ULN < bili ≤3 × ULN), and severe (3 × ULN < bili < 10 × ULN) liver dysfunction